MSD (UK) Limited (United Kingdom)
In research, MSD (UK) Limited (United Kingdom) stands highest in Life Sciences (#2,224 of 14,347 worldwide), Neuroscience (#767 of 2,675 worldwide) and Medicine (#8,680 of 17,978 worldwide), over all time.
- World rank, all time
- #5,750 of 42,892
- Rank in United Kingdom
- #360 of 2,253
- Research works
- 1k ▼ 21% vs 2013–17
- Citations
- 43k 42.1 per fractional work
- Top-10% rate
- 11.4% record average 16.5%
- Open access
- 19% world 28%
What is MSD (UK) Limited (United Kingdom) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| Life SciencesDomain | #2,224 of 14,347 | 22.5% | 493 | |
| NeuroscienceField | #767 of 2,675 | 26.5% | 218 | |
| MedicineField | #8,680 of 17,978 | 20.9% | 245 | |
| Biochemistry, Genetics and Molecular BiologyField | #3,943 of 7,814 | 19.2% | 223 | |
| Physical SciencesDomain | #11,135 of 21,541 | 13.6% | 236 | |
| Health SciencesDomain | #11,194 of 20,462 | 20.0% | 264 | |
| Cellular and Molecular NeuroscienceSubfield | #533 of 945 | 23.5% | 159 | |
| Molecular BiologySubfield | #3,039 of 4,961 | 19.1% | 187 | |
| Organic ChemistrySubfield | #1,739 of 2,025 | 11.6% | 155 | |
| ChemistryField | #2,895 of 3,369 | 12.5% | 191 |
Each strip is that field’s whole ranked pool, with the notch where MSD (UK) Limited (United Kingdom) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 6.2×. Every wedge is a field page.
- Economics, Econometrics and Finance 6.2×
- Immunology and Microbiology 3.5×
- Medicine 3.2×
- Mathematics 1.6×
- Neuroscience 1.3×
- Biochemistry, Genetics and Molecular Biology 1.2×
- Decision Sciences 0.9×
- Pharmacology, Toxicology and Pharmaceutics 0.7×
- Health Professions 0.7×
- Chemistry 0.5×
- Nursing 0.5×
- Environmental Science 0.3×
- Engineering 0.2×
- Computer Science 0.1×
- Social Sciences 0.1×
- Agricultural and Biological Sciences 0.1×
- Psychology 0.1×
- Business, Management and Accounting 0.0×
Who are the top researchers at MSD (UK) Limited (United Kingdom)?
Ranked on the composite score, Paul D. Leeson, Gerard R. Dawson and Alan P. Watt lead among researchers whose main affiliation is MSD (UK) Limited (United Kingdom).
- 1 Paul D. Leeson United Kingdom · #107,107 worldwide 259 citations · 33 works
- 2 Gerard R. Dawson United Kingdom · #345,693 worldwide 115 citations · 34 works
- 3 Alan P. Watt United Kingdom · #373,831 worldwide 79 citations · 20 works
- 4 Ruth M. McKernan United Kingdom · #374,617 worldwide 148 citations · 19 works
- 5 Keith A. Wafford United Kingdom · #720,718 worldwide 111 citations · 17 works
- 6 Stanley H. B. Wright United Kingdom · #1,006,237 worldwide 28 citations · 16 works
- 7 W. J. C. Currie United Kingdom · #1,132,802 worldwide 18 citations · 15 works
- 8 David S. Reynolds United Kingdom · #1,150,029 worldwide 35 citations · 15 works
- 9 M. J. Vandenburg United Kingdom · #1,305,779 worldwide 10 citations · 15 works
- 10 Michael Rowley United Kingdom · #1,339,852 worldwide 35 citations · 20 works
Which keywords describe research at MSD (UK) Limited (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Clinical Practice Guidelines, Chemotherapy, Tumor Microenvironment, Cost of Care, Financial Toxicity, Cost-effectiveness Analysis and Health Utility Measures.
- Oropharyngeal Cancer
- Clinical Management
- Targeted Therapy
- Sentinel Lymph Node Biopsy
- Pulmonary Hypertension
- Echocardiography
- Chronic Kidney Disease
- Rituximab
- Cetuximab
- Global Burden
- Immunotherapy
- Cervical Cancer
- Antimicrobial Resistance
- Clinical Trials
- PD-1 and PD-L1
- Treatment Guidelines
- Cost-effectiveness Analysis
- Cost of Care
- Clinical Practice Guidelines
- Quality of Life
- Epidemiology
- Chemotherapy
- Tumor Microenvironment
- Financial Toxicity
- Health Utility Measures
- Immune Checkpoint Blockade
- Prognostic Factors
- Human Papillomavirus
- Cancer Incidence
- Classification
- Radiotherapy
- Survival Analysis
- Respiratory Infections
- Vaccination
- Community-Acquired Pneumonia
- Pneumococcal Conjugate Vaccine
- Right Heart Assessment
- Survival Prediction
- Survival
- Lymphoma
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology8▲ 4.5×32 topics
- Quality of Life3▲ 4.3×5 topics
- Chemotherapy3▲ 8.4×14 topics
- Clinical Practice Guidelines3▲ 11×7 topics
- Tumor Microenvironment3▲ 13×5 topics
- Cost of Care2▲ 184×1 topic
- Financial Toxicity2▲ 184×1 topic
- Cost-effectiveness Analysis2▲ 59×1 topic
- Health Utility Measures2▲ 59×1 topic
- Treatment Guidelines2▲ 22×3 topics
- Immune Checkpoint Blockade2▲ 41×1 topic
- PD-1 and PD-L12▲ 41×1 topic
- Prognostic Factors2▲ 10.0×8 topics
- Clinical Trials2▲ 6.3×10 topics
- Human Papillomavirus2▲ 35×2 topics
- Antimicrobial Resistance2▲ 19×5 topics
- Cancer Incidence2▲ 28×3 topics
- Cervical Cancer2▲ 34×2 topics
- Classification2▲ 7.8×2 topics
- Immunotherapy2▲ 5.0×8 topics
- Radiotherapy2▲ 9.1×5 topics
- Global Burden2▲ 6.0×4 topics
- Survival Analysis2▲ 12×4 topics
- Cetuximab1▲ 36×2 topics
- Respiratory Infections1▲ 26×2 topics
- Rituximab1▲ 20×2 topics
- Vaccination1▲ 41×2 topics
- Chronic Kidney Disease1▲ 11×2 topics
- Community-Acquired Pneumonia1▲ 79×1 topic
- Echocardiography1▲ 9.9×2 topics
- Pneumococcal Conjugate Vaccine1▲ 79×1 topic
- Pulmonary Hypertension1▲ 19×2 topics
- Right Heart Assessment1▲ 66×1 topic
- Sentinel Lymph Node Biopsy1▲ 30×2 topics
- Survival Prediction1▲ 66×1 topic
- Targeted Therapy1▲ 12×3 topics
- Survival1▲ 17×2 topics
- Clinical Management1▲ 13×4 topics
- Lymphoma1▲ 14×3 topics
- Oropharyngeal Cancer1▲ 43×1 topic
Which research topics does MSD (UK) Limited (United Kingdom) publish most on?
By volume in 2022–2025: Economic and Financial Impacts of Cancer, Health Systems, Economic Evaluations, Quality of Life, Cancer Immunotherapy and Biomarkers and Pneumonia and Respiratory Infections.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Economic and Financial Impacts of Cancer Economics and Econometrics 2 works
- 2 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 4 Pneumonia and Respiratory Infections Epidemiology 1 works
- 5 Pulmonary Hypertension Research and Treatments Pulmonary and Respiratory Medicine 1 works
- 6 Inhalation and Respiratory Drug Delivery Pulmonary and Respiratory Medicine 1 works
- 7 Head and Neck Cancer Studies Otorhinolaryngology 1 works
- 8 ECG Monitoring and Analysis Cardiology and Cardiovascular Medicine 1 works
- 9 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 10 Cervical Cancer and HPV Research Epidemiology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has MSD (UK) Limited (United Kingdom)'s research output changed?
Output in 2018–2022 was 21% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Hoddesdon
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.